compounded semaglutide weight loss effectiveness Levity Review The FDA's Decision to Ban

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

By activating these receptors in the brains satiety centers (like the area postrema), it promotes feelings of fullness, reduces food intake, and helps stabilize post-meal blood sugar spikes, making it a promising candidate for weight management, particularly in combination with the GLP-1 receptor agonist semaglutide (marketed as CagriSema)

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

But in the right hands providers who understand both mental health and metabolic medicine they can be transformative